https://joapponline.com/index.php/joapp/issue/feedJournal of Applied Pharmacognosy and Phytochemistry2026-11-14T23:34:07-05:00Mr. Aarush Basnetadmin@joapponline.comOpen Journal Systems<p><strong>Journal of Applied Pharmacognosy and Phytochemistry</strong> (JOAPP)<em> </em>is an official publication of Creative Pharma Assent (CPA). It is an open access, peer reviewed online Journal. JOAPP primarily focuses on publication of manuscript related to Pharmacognostic and Phytochemical investigations plants having medicinal values, bioactive phytochemicals, herbal medicine, traditional medicine, modern analytical techniques used in identification, extraction and isolation of plants, plants biochemistry, biosynthesis, molecular biology and new drug discovery related to natural product. JOAPP publishes issues quarterly.</p> <p>The aim of the scientific journal, is to present a wide platform for the researchers to share their valuable research work and findings in form of research papers, review articles and short communications. JOAPP publishes manuscripts based on original works with a definite innovation and novelty after thorough peer review process & plagiarism checking. The paper must have a suitable and proper scientific background.</p> <p><strong>Brief Information about JOAPP</strong></p> <ul> <li><strong>Journal Title: </strong><strong>Journal of Applied Pharmacognosy and Phytochemistry (JOAPP)</strong></li> <li><strong>Journal Abbreviation: J Appl Pharmcog Phytochem<br /></strong></li> <li><strong>Publisher: </strong>Creative Pharma Assent</li> <li><strong>Country: </strong>India</li> <li><strong>Language: </strong>English</li> <li><strong>Publishing Frequency: </strong>Quarterly</li> <li><strong>Editorial Office: </strong>Plot No. 105/42, Opposite electricity substation, Changorabhata, Raipur (CG) 492001, India</li> <li><strong>Regional Office:</strong> Bishnupath, Rukminigoan, Dispur, Guwahati, Assam, PIN-781022</li> <li><strong>Phone: </strong>+91-8349444385 ; +91-9770019143</li> <li><strong>E-mail: </strong>joapp.editor@gmail.com ; editor@joapponline.com</li> <li><strong>Website: </strong>https://joapponline.com</li> <li><strong>Publication: </strong>Online only</li> <li><strong>Year of Start: </strong>2020</li> <li><strong>Review Process: </strong>Double-blind peer review</li> </ul>https://joapponline.com/index.php/joapp/article/view/72Flavonoids as multi-target therapeutic agents: A systematic review of pharmacological evidence, molecular mechanisms, and clinical translation2026-11-14T23:34:07-05:00Jahnabi Sarmahdhiraj.b@adtu.inDhiraj Bishyadhiraj.b@adtu.inRosamund Jyrwadhiraj.b@adtu.inIkram Hussaindhiraj.b@adtu.in<p><strong>Background:</strong> Flavonoids, the largest class of plant polyphenols, are increasingly recognized as multi-target therapeutic agents that can modulate diverse molecular pathways involved in chronic diseases. Unlike previous reviews focusing on individual flavonoid subclasses or specific diseases, this systematic review provides a comprehensive evaluation of their molecular mechanisms, pharmacokinetics, network pharmacology, and clinical applications. <strong>Methodology:</strong> We conducted a systematic review following the PRISMA 2020 guidelines. We searched electronic databases, including PubMed, Scopus, Web of Science, Embase, ScienceDirect, Cochrane Library, and Google Scholar, for studies published between January 2000 and March 2024. We assessed eligible in vitro, in vivo, and clinical studies using established risk-of-bias tools and evaluated evidence certainty using the GRADE framework. <strong>Results and Discussion:</strong> The review identified extensive preclinical evidence and an emerging body of clinical studies supporting flavonoids' therapeutic potential. These compounds modulate multiple molecular targets, including inflammatory mediators, kinase signaling pathways, transcription factors, and apoptotic regulators, across cancer, cardiovascular, metabolic, neurodegenerative, and inflammatory disorders. Clinical studies indicate modest but promising therapeutic benefits; however, poor oral bioavailability, rapid metabolism, and heterogeneity in study design and intervention protocols constrain broader clinical translation. <strong>Conclusion:</strong> Flavonoids demonstrate substantial multi-target therapeutic potential supported by robust mechanistic evidence and encouraging clinical findings. Nevertheless, well-designed, adequately powered clinical trials, standardized formulations, and advanced bioavailability-enhancing delivery systems are essential to establish their efficacy and facilitate widespread clinical application.</p>2026-11-15T00:00:00-05:00Copyright (c) 2024 Jahnabi Sarmah, Dhiraj Bishya, Rosamund Jyrwa, Ikram Hussainhttps://joapponline.com/index.php/joapp/article/view/30Gene therapy: credibility or curse?2023-11-14T21:09:31-05:00Ameena Ahmedameena7002@gmail.comMrinmoy Pratim Chetiamrinmoyprc@gmail.comSatyabrat Sarmasatyabratsarma17@gmail.com<p><strong>Background: </strong>Gene therapy is a promising therapeutic approach that involves introducing functional genetic material into defective or diseased cells to treat or prevent disease. Recent advances have led to significant success in managing inherited disorders such as cystic fibrosis, alpha-1 antitrypsin deficiency, hemophilia, beta-thalassemia, and sickle cell disease, and have also shown potential in treating cancers and infectious diseases, including HIV. Several gene therapy products have received regulatory approval for clinical use; however, concerns regarding their long-term efficacy and safety remain. <strong>Methodology: </strong>This review summarizes the current status of gene therapy by discussing major therapeutic approaches, including ex vivo and in vivo gene delivery, genome editing, somatic gene therapy, and germline gene therapy. It also examines the clinical outcomes of approved gene therapies and evaluates their associated safety challenges. <strong>Results and Discussion: </strong>Advances in gene therapy have demonstrated encouraging clinical outcomes, particularly for inherited genetic disorders. Somatic gene therapy has shown promising efficacy and an acceptable safety profile in approved clinical applications. In contrast, germline gene therapy still faces substantial technical, ethical, and safety concerns, limiting its clinical translation despite its potential to prevent hereditary diseases. <strong>Conclusion: </strong>Gene therapy represents a transformative strategy for treating genetic and acquired diseases. While somatic gene therapy has become a viable clinical option, germline gene therapy requires further technological refinement and rigorous safety evaluation before widespread clinical application. Continued research is expected to improve the safety, efficacy, and therapeutic potential of gene-based interventions.</p>2026-11-15T00:00:00-05:00Copyright (c) 2024 Ameena Ahmed, Mrinmoy Pratim Chetia, Satyabrat Sarma